 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Incruse Ellipta |
| Other names | GSK573719A |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Inhalation (DPI) |
| Drug class | Long-acting muscarinic antagonist (LAMA)[1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | ~89%[2] |
| Metabolism | Liver (CYP2D6) |
| Elimination half-life | 11 hours |
| Excretion | Feces (58%) and urine (22%) |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C29H34BrNO2 |
| Molar mass | 508.500 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Umeclidinium, sold under the trade name Incruse Ellipta, is a medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[1] It is not used for asthma.[1] It is used by breathing the medication into the lungs.[1]
Side effects may include change in taste, cough, and eye pain.[1][3] Severe side effects may include anaphylaxis, bronchospasm, urinary retention, and glaucoma.[1] It is not recommended in those with severe milk protein allergies.[1] It is a long-acting muscarinic antagonist (LAMA).[1]
Umeclidinium was approved for medical use in the United States in 2014.[1] It is on the World Health Organization's List of Essential Medicines as an alternative to tiotropium.[4] In the United Kingdom a month of medication costs the NHS about £28 while in the United States this amount is about 380 USD.[3][5] It is also available in combination as umeclidinium/vilanterol[1][6] and fluticasone/umeclidinium/vilanterol.[7]
References edit
- ^ a b c d e f g h i j k l "Umeclidinium Monograph for Professionals". Drugs.com. Archived from the original on 27 January 2021. Retrieved 13 August 2021.
- ^ "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Archived from the original (PDF) on 10 July 2018. Retrieved 22 February 2016.
- ^ a b c BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 263. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "Incruse Ellipta Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 29 August 2021. Retrieved 30 August 2021.
- ^ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282.
- ^ "TRELEGY ELLIPTA Package Insert" (PDF). GlaxoSmithKline. September 2017. Archived (PDF) from the original on 12 July 2020. Retrieved 11 July 2020.